Accelerated partial breast irradiation

Phase 2Small molecule

Accelerated partial breast irradiation is one of 4 small molecule programs targeting Brachytherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BrachytherapyRecruiting

BrachytherapyPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Brachytherapy

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

1 2

Keytruda

Merck & Co.

Phase 2

1 3

Accelerated partial breast irradiation

VVirginia Commonwealth University

Phase 2

1 4

Dcfpyl

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2033

Phase 2Recruiting

Brachytherapy

NCT06185205

Clinical

Trials by Indication[1]

Brachytherapy1 trial

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

Recruiting·VVirginia Commonwealth University·Phase 2·NCT06185205·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Accelerated partial breast irradiation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Accelerated partial breast irradiation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Accelerated partial breast irradiation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Virginia Commonwealth University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVirginia Commonwealth University

Accelerated partial breast irradiation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2033

Trials by Indication[1]

Brachytherapy1 trial

References

Drug Info

Quick Facts

Related News